KESTRA MED TECHNOLOGIES LTD SEC Filings

Kestra Medical Technologies (KMTS)Timothy P. Moran, who serves as Chief Business Officer. The filing states “No securities are beneficially owned.” The date of event is 11/03/2025. This is an administrative disclosure under Section 16 reporting Mr. Moran’s starting beneficial ownership status with the company.

Kestra Medical Technologies (KMTS) filed an 8‑K under Regulation FD, furnishing a press release titled “Largest Real-World Study of Wearable Defibrillators Confirms Strong Effectiveness and Safety Performance of Kestra’s ASSURE Device.” The release announces primary results from the ACE‑PAS post‑approval study, presented as late‑breaking science at the American Heart Association Scientific Sessions 2025 in New Orleans.

The press release is furnished as Exhibit 99.1 and, as noted, is not deemed “filed” for Section 18 liability purposes or incorporated by reference unless specifically stated. The filing includes customary forward‑looking statements language and directs readers to risk factors in the company’s Form 10‑K for the fiscal year ended April 30, 2025.

FMR LLC and Abigail P. Johnson reported beneficial ownership of 5,225,988 shares of Kestra Medical Technologies Inc. common stock, representing 10.2% of the class as of the event date 09/30/2025. The filing shows FMR LLC holds 5,225,753 shares with sole voting power and 5,225,988 shares with sole dispositive power; Abigail P. Johnson is reported with sole dispositive power over the same 5,225,988 shares. The statement is filed on Schedule 13G (Amendment No. 1), indicating the position is held in the ordinary course of business and not for the purpose of changing or influencing control. Signatures indicate filings were executed on 10/06/2025 and reference powers of attorney attached to earlier Schedule 13G filings.

Amended Form 4 for Alfred J. Ford Jr. at Kestra Medical Technologies (KMTS). The filing retroactively reports the purchase of 20,000 common shares on 03/07/2025 at a price of $17.00 per share, acquired under the issuer's initial public offering reserved share program. Following this transaction, the reporting person beneficially owns 49,412 common shares in a direct capacity. The amendment states the shares were inadvertently omitted from prior filings. The form is signed by an attorney-in-fact for the reporting person.

Traci S. Umberger, General Counsel and Chief Administrative Officer and a director, reported an amended Form 4 correcting prior filings to show purchase of 13,500 common shares of Kestra Medical Technologies, Ltd. The transaction occurred on 03/07/2025 at $17.00 per share under the issuer's initial public offering reserved share program. Following the reported purchase, Umberger beneficially owned 134,336 common shares, held directly. The amendment states the shares were inadvertently omitted from prior filings and are now disclosed.

Kestra Medical Technologies director Mary Kay Ladone acquired 10,909 restricted stock units (RSUs) on 09/04/2025, each converting into one common share and scheduled to vest on September 4, 2026, subject to continued service. The filing also reports that 12,994 restricted common shares were automatically converted in connection with the issuer's initial public offering from previously held Class A Common Units granted October 7, 2024. Those converted restricted shares vest in three tranches: 4,331 on October 7, 2025; 4,331 on October 7, 2026; and 4,332 on October 7, 2027. The form is signed by the reporting person and identifies her as a director.

Raymond W. Cohen, a director of Kestra Medical Technologies, Ltd. (KMTS), reported two equity transactions. He purchased 17,000 common shares at $17.00 on 03/07/2025 that were reserved under the issuer's IPO reserved share program and were inadvertently omitted from earlier filings. He also received 10,909 restricted stock units (RSUs) on 09/04/2025; each RSU converts into one common share and the RSUs vest on 09/04/2026 subject to continued service. The report shows 29,994 shares beneficially owned after the March purchase and 40,903 shares beneficially owned following the RSU grant.

Conor Hanley, a director of Kestra Medical Technologies, Ltd. (KMTS), reported acquisition of 13,120 restricted stock units (RSUs) on 09/04/2025. The filing states each RSU converts to one common share. Following the reported grant, Hanley beneficially owns 13,120 shares attributable to these RSUs. The award vests in two tranches: 2,212 RSUs vest on 06/04/2026 and 10,908 RSUs vest on 09/04/2026, each contingent on continued service through the vesting date. The Form 4 was signed by an attorney-in-fact on 09/08/2025.